Age-related changes of the optic nerve fibres were studied in 3-month-old (young), 12-month-old (adult) and 24-month-old (aged) male Sprague-Dawley rats. The optic nerve was harvested with particular care from the intracranial portion. Cross sections from the optic nerve of animals of different age groups were stained with toluidine blue and examined under a light microscope at low and high magnification. Other sections were stained for the demonstration of glial cells using the method described by Holzer. A third group of sections were stained by the immunohistochemical method to detect glial fibrillary acidic protein, which is a marker for localising and characterising astrocytes. All these morphological results were subjected to the quantitative analysis of images and to statistical analysis of the values to identify significant morphometric data. Biochemical dosages of proteins were also performed on homogenised fragments of the optic nerve. Our results demonstrate that the following age-related changes can be observed: (1) an increase in meningeal membranes, (2) an increased number of astrocytes, (3) an increase in areal density of glial fibrillary acidic protein immunoreactivities, (4) an increased thickness of the entire optic nerve and an increased area of the nerve, (5) a decreased number of nerve fibres and (6) a decrease in the nerve fibre/meningeal membrane ratio from 3:1 to 1:1. Moreover, the amount of protein does not change with age. The rat optic nerve, therefore, appears sensitive to aging processes.

Keywords:
Optic nerve, Histology, Aging
1.
Sefton AJ, Dreher B: Visual system; in Paxinos G (ed): The Rat Nervous System. New York, Academic Press, 1985, vol 1, pp 169–221.
2.
Dolman CL, McCormick AQ, Drance SM: Aging of the optic nerve. Arch Ophthalmol 1980;98:2053–2058.
3.
Balazsi AG, Rootman J, Drance SM: The effect of age on the nerve fiber population of the human optic nerve. Am J Ophthalmol 1984;97:760–766.
4.
Johnson BM, Miao M, Sadun AA: Age related decline of human optic nerve axon populations. Age 1987;10:5–9.
5.
Repka MX, Quigley HA: The effect of age on normal human optic nerve fiber number and diameter. Ophthalmology 1989;96:26–31.
6.
Lai Y, Jacoby RO, Jonas AM: Age related and light associated retinal changes in Fisher 344 rats. Invest Ophthalmol Vis Sci 1978;17:634–638.
7.
Shinowara NL, London ED, Rapaport SI: Changes in retinal morphology and glucose utilization in aging albino rats. Exp Eye Res 1982;34:517–530.
8.
Weisse I, Stoetzer H, Seitz R: Age- and light-dependent changes in the rat eye. Virchows Arch 1974;362:145–156.
9.
Katz ML, Robinson WG: Evidence of cell loss from the rat retina during senescence. Exp Eye Res 1986;42:293–304.
10.
Millonig G: Advantages of a phosphate buffer for OsO4 solutions in fixation. J Appl Physiol 1961;32:1637–1641.
11.
Holzer W: Über eine neue Methode der Gliafaserfärbung. Z Neurol Psychiatry 1921;69:354–366.
12.
Sobin LH: AFIP Laboratory Methods in Histotechnology. Washington, American Registry of Pathology, 1992, pp 102–104.
13.
Coons AH, Leduc EH, Connolly JM: Studies on antibody production. I. A method for the histochemical demonstration of specific antibody and its application to a study of the hyperimmune rabbit. J Exp Med 1955;102:49–60.
14.
Lowry OH, Rosebrough NJ, Farr AL, Randall J: Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265–275.
15.
Manual of Methods of Quantimet Leica. Cambridge, Microsystems Imaging Solutions, 1997.
16.
Serio A: Appunti dalle lezioni di statistica sanitaria. Roma, Kappa, 1986.
17.
Castino M, Roletto E: Statistica applicata. Padova, Piccin, 1992.
18.
Hernandez HA, Pena J: The optic nerve head in glaucomatous optic neuropathy. Arch Ophthalmol 1997;115:389–395.
19.
Amaducci L, Forno KI, Eng LF: Glial fibrillary acidic protein in cryogenic lesions of the rat brain. Neurosci Lett 1981;21:27–32.
20.
Aquino DA, Chu FC, Brosnan CF, Norton WT: Glial fibrillary acidic protein increases in the spinal cord of Lewis rats with acute experimental autoimmune encephalitis. J Neurochem 1988;51:1085–1096.
21.
Liu KM, Shen CL: Ultrastructural sequence of myelin breakdown during wallerian degeneration in the rat optic nerve. Cell Tissue Res 1985;242:245–256.
22.
Shen CL, Liu KM: Neuroglia of the adult rat optic nerve in the course of wallerian degeneration. Proc Natl Sci Counc Repub China B 1984;8:324–334.
23.
Ni SYK, Duher B: Morphology of rat retinal ganglion cells projecting to the thalamus and midbrain. Proc Aust Physiol Pharmacol Soc 1981;12:94–97.
24.
Fukuda Y, Sugimoto T, Shirokawa T: Strain differences in quantitative analysis of the rat optic nerve. Exp Neurol 1982;75:525–532.
25.
Sefton AJ, Swinburn M: Electrical activity of lateral geniculate nucleus and optic tract of the rat. Vision Res 1964;4:315–328.
26.
Katz ML, Robinson WG: Evidence of cell loss from the rat retina during senescence. Exp Eye Res 1986;42:293–304.
27.
Peters A, Feldman ML, Vaughan DW: Effect of ageing on the neuronal population within area 17 of adult rat cerebral cortex. Neurobiol Aging 1983;4:273–282.
28.
Farris EJ, Griffith JQ: The Rat in Laboratory Investigations. New York, Hafner, 1962.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.